DermTech Management to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

DermTech Management to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

LA JOLLA, Calif.–(BUSINESS WIRE)–
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 1:00 p.m. Eastern Time.

Interested parties may access a live webcast of the presentation and, for 90 days following the BTIG Conference, an archived webcast of the presentation through the “Investor Relations” section of DermTech’s website at: www.DermTech.com.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: DermTech’s plans to attend investor conferences, and the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

DermTech

Sarah Dion

[email protected]

858.450.4222

Westwicke Partners IR

Caroline Corner, PhD

[email protected]

415.202.5678

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Medical Supplies Medical Devices Health Genetics Biotechnology

MEDIA:

Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Therapeutics”) entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with its primary product liability insurer, Navigators Specialty Insurance Company and Navigators Insurance Company (“Navigators”).

The Settlement Agreement resolves the previously disclosed declaratory judgment action that Navigators filed in 2019, and Assertio Therapeutics’ related counterclaims, stemming from a dispute as to whether the opioid lawsuits brought against Assertio Therapeutics beginning in May 2018 are covered under its life sciences liability policies with Navigators.

Pursuant to the Settlement Agreement, Navigators has agreed to pay $5.0 million of its $10.0 million primary policy to Assertio Therapeutics by February 17, 2021.

“We are very pleased with this outcome,” said Dan Peisert, President and Chief Executive Officer of Assertio. “It is an important recovery for the Company and does not affect our ability to pursue other sources of recovery, including the excess layers of our insurance.”

The Company is updating its previously stated range for the cost of the restructuring announced on December 15, 2020 from $8.0 to $10.0 million to $11.0 to $12.0 million to account for additional non-cash charges relating to the write-off of certain office lease and furniture assets. In addition, the Company has determined certain events existed at the end of fiscal year 2020 representing a triggering event for an impairment assessment of its long-lived assets and goodwill. Although the Company has not yet completed its impairment assessment, it expects to recognize a non-cash impairment charge of no less than $9.0 million for the quarterly period ended December 31, 2020.

About Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. To learn more about Assertio, visit www.assertiotx.com.

Investor Contact

Max Nemmers
[email protected]

Forward Looking Statements

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio. These risks are more fully described in the joint proxy statement/prospectus filed with the SEC in connection with the Merger and Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.



EMCORE Reports Fiscal 2021 First Quarter Results

ALHAMBRA, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) — EMCORE Corporation (Nasdaq: EMKR), a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets, today announced results for the fiscal 2021 first quarter ended December 31, 2020 (1Q21). Management will host a conference call to discuss financial and business results tomorrow, Thursday, February 4, 2021, at 8:00 AM Eastern Time.

Consolidated revenue for 1Q21 was $33.4 million, comprised of $13.6 million from the Aerospace & Defense segment and $19.8 million from the Broadband segment. Net income on a GAAP and non-GAAP basis was $2.6 million and $3.4 million, respectively, in 1Q21 compared with a net income on a GAAP and non-GAAP basis of $0.7 million and $2.9 million, respectively, in 4Q20. Adjusted EBITDA was positive $4.4 million in 1Q21.

“The EMCORE team executed well in 1Q21 combining and gross margin consistency with lower operating expenses to drive strong sequential-quarter earnings growth,” said Jeff Rittichier, Chief Executive Officer of EMCORE. “We continued to overcome COVID-19 related challenges in our supply chain and operations, and made good progress on product qualification and new programs capture despite the COVID headwinds. We remain excited and confident about the growth prospects across our Aerospace & Defense product portfolio. On the Broadband side, we have strong order book for our Cable TV products through the September 2021 quarter with MSOs favoring proven linear optics to provide the network bandwidth that customers need,” concluded Rittichier.


Consolidated Results

       
  Three Months Ended  
  Dec 31, 2020 Sep 30, 2020 + increase /
  1Q21 4Q20 – decrease
Revenue $33.4M $33.5M -$0.1M
Gross Margin   38%     37%     +1%  
Operating Expenses $10.1M $11.9M -$1.8M
Operating Margin   8%     2%     +6%  
Net Income $2.6M $0.7M +$1.9M
Earnings Per Share Basic   $0.09     $0.02     +$0.07  
Earnings Per Share Diluted   $0.08     $0.02     +$0.06  
Non-GAAP Gross Margin (1)   38%     38%      
Non-GAAP Operating Expenses (1) $9.3M $9.7M -0.4M
Non-GAAP Operating Margin (1)   10%     9%     +1%  
Non-GAAP Net Income (1) $3.4M $2.9M +$0.5M
Non-GAAP Earnings Per Share Basic (1)   $0.12     $0.10     +$0.02  
Non-GAAP Earnings Per Share Diluted (1)   $0.11     $0.10     +$0.01  
Adjusted EBITDA $4.4M $4.0M +$0.4M
Ending Cash and Cash Equivalents $31.2M $30.5M +$0.7M
Loan Payable $6.5M $6.5M    
(1) Please refer to the schedules at the end of this press release for complete GAAP to non-GAAP reconciliations and other
information related to non-GAAP financial measures.
 


Aerospace and Defense (A&D) Segment

A&D’s sequential-quarter revenue decrease was primarily due to lower sales of Navigation products. A&D’s gross margin decreased slightly, primarily due to the lower revenue.

       
  Three Months Ended  
  Dec 31, 2020 Sep 30, 2020 + increase /
  1Q21 4Q20 – decrease
A&D Segment Revenue $13.6M $14.5M -$0.9M
A&D Segment Gross Margin 30 % 31 % -1 %
A&D Segment R&D Expense (2) $3.7M $5.6M -$1.9M
A&D Segment Profit $0.4M -$1.1M +$1.5M
Non-GAAP A&D Segment Gross Margin (1) 31 % 32 % -1 %
Non-GAAP A&D Segment R&D Expense (1) $3.6M $4.0M -$0.4M
Non-GAAP A&D Segment Profit $0.6M $0.6M  
(1) Please refer to the schedules at the end of this press release for complete GAAP to non-GAAP
reconciliations and other information related to non-GAAP financial measures.
(2) Individual components may not sum to the total of reported consolidated amounts due to rounding.


Broadband Segment

Broadband’s sequential-quarter revenue increase was primarily driven by higher sales of Cable TV optical transmitters and components. Broadband’s gross margin increased slightly, primarily driven by the higher revenue.

       
  Three Months Ended  
  Dec 31, 2020 Sep 30, 2020 + increase /
  1Q21 4Q20 – decrease
Broadband Segment Revenue $19.8M $19.0M +$0.8M
Broadband Segment Gross Margin 43 % 42 % +1 %
Broadband Segment R&D Expense (2) $0.6M $0.7M -$0.1M
Broadband Segment Profit $7.9M $7.3M +$0.6M
Non-GAAP Broadband Segment Gross Margin (1) 43 % 42 % +1 %
Non-GAAP Broadband Segment R&D Expense (1) $0.5M $0.6M -$0.1M
Non-GAAP Broadband Segment Profit $8.0M $7.4M +$0.6M
(1) Please refer to the schedules at the end of this press. release for complete GAAP to non-GAAP
reconciliations and other information related to non-GAAP financial measures.
(2) Individual components may not sum to the total of reported consolidated amounts due to rounding.


Business Outlook

The Company expects revenue for the fiscal second quarter ending March 31, 2021 to be in the range of $34 million to $36 million.


Conference Call

The Company will discuss its financial results on February 4, 2021 at 8:00 a.m. ET (5:00 a.m. PT). The call will be available, live, to interested parties by dialing 866-248-8441. For international callers, please dial +1 323-289-6576. The conference passcode number is 8047032. The call will be webcast live via the Company’s website at http://www.emcore.com. A webcast will be available for replay beginning Thursday, February 4, 2021 following the conclusion of the call.


About EMCORE

EMCORE Corporation is a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets. Our best-in-class components and systems support a broad array of applications including navigation and inertial sensing, defense optoelectronics, broadband transport, 5G wireless infrastructure, optical sensing, and cloud data centers. We leverage industry-leading Quartz MEMS, Lithium Niobate and Indium Phosphide chip-level technology to deliver state-of-the-art component and system-level products across our end-market applications. EMCORE has vertically-integrated manufacturing capability at its wafer fabrication facility in Alhambra, CA, and Quartz MEMS manufacturing facility in Concord, CA. Our manufacturing facilities maintain ISO 9001 quality management certification, and we are AS9100 aerospace quality certified at our facility in Concord. For further information about EMCORE, please visit http://www.emcore.com.


Use of Non-GAAP Financial Measures

The Company conforms to U.S. Generally Accepted Accounting Principles (“GAAP”) in the preparation of its financial statements. We disclose supplemental non-GAAP earnings measures for gross profit margin, operating expenses, operating profit margin, net income, and earnings per share, as well as adjusted EBITDA.

Management believes these supplemental non-GAAP measures reflect the Company’s core ongoing operating performance and facilitates comparisons across reporting periods. The Company uses these measures when evaluating its financial results and for planning and forecasting of future periods. We believe that these supplemental non-GAAP measures are also useful to investors in assessing our operating performance. While we believe in the usefulness of these supplemental non-GAAP measures, there are limitations. Our non-GAAP measures may not be reported by other companies in our industry and/or may not be directly comparable to similarly titled measures of other companies due to potential differences in calculation. We compensate for these limitations by using these non-GAAP measures as a supplement to GAAP and by providing the reconciliations to the most comparable GAAP measure.

The schedules at the end of this press release reconcile the Company’s non-GAAP measures to the most directly comparable GAAP measure. The adjustments share one or more of the following characteristics: they are unusual and the Company does not expect them to recur in the ordinary course of its business, they do not involve the expenditure of cash, they are unrelated to the ongoing operation of the business in the ordinary course, or their magnitude and timing is largely outside of the Company’s control. For all reporting periods disclosed, the Company has applied consistent rationale, method, and adjustments in reconciling non-GAAP measures to the most directly comparable GAAP measure.

Non-GAAP measures are not in accordance with or an alternative to GAAP, nor are they meant to be considered in isolation or as a substitute for comparable GAAP measures. Our disclosures of these measures should be read only in conjunction with our financial statements prepared in accordance with GAAP. Non-GAAP measures should not be viewed as a substitute for the Company’s GAAP results.


Forward-Looking Statements

The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). These forward-looking statements are largely based on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Such forward-looking statements include, in particular, projections about our future results, statements about our plans, strategies, business prospects, changes and trends in our business and the markets in which we operate.

These forward-looking statements may be identified by the use of terms and phrases such as “anticipates”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “plans”, “projects”, “targets”, “will”, and similar expressions or variations of these terms and similar phrases. Additionally, statements concerning future matters such as projected financial results, the development of new products, enhancements or technologies, sales levels, expense levels and other statements regarding matters that are not historical are forward-looking statements. We caution that these forward-looking statements relate to future events or our future financial performance and are subject to business, economic, and other risks and uncertainties, both known and unknown, that may cause actual results, levels of activity, performance or achievements of our business or our industry to be materially different from those expressed or implied by any forward-looking statements.

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, including without limitation, the following: (a) the rapidly evolving markets for the Company’s products and uncertainty regarding the development of these markets; (b) the Company’s historical dependence on sales to a limited number of customers and fluctuations in the mix of products and customers in any period; (c) delays and other difficulties in commercializing new products; (d) the failure of new products: (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, (iii) to be qualified and accepted by our customers, and (iv) to successfully compete with products offered by our competitors; (e) uncertainties concerning the availability and cost of commodity materials and specialized product components that we do not make internally; (f) actions by competitors; (g) risks and uncertainties related to applicable laws and regulations, including the impact of changes to applicable tax laws and tariff regulations; (h) acquisition-related risks, including that (i) the revenues and net operating results obtained from our acquisition of the Systron Donner Inertial (“SDI”) business may not meet our expectations, (ii) the costs and cash expenditures for integration of the SDI business operations may be higher than expected, (iii) there could be losses and liabilities arising from the acquisition of SDI that we will not be able to recover from any source, and (iv) we may not realize sufficient scale in our navigation systems product line from the SDI acquisition and will need to take additional steps, including making additional acquisitions, to achieve our growth objectives for this product line; (i) risks related to our ability to obtain capital; (j) risks related to the transition of certain of our manufacturing operations from our Beijing facility to a contract manufacturer’s facility; (k) the outbreak of COVID-19 and the impact on our business and operations, which is evolving and beyond our control; and (l) other risks and uncertainties discussed under Item 1A – Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as updated by our subsequent periodic reports.

Forward-looking statements are based on certain assumptions and analysis made in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate under the circumstances. While these statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any events or financial results. All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and subsequent facts or circumstances may contradict, obviate, undermine, or otherwise fail to support or substantiate such statements. We caution you not to rely on these statements without also considering the risks and uncertainties associated with these statements and our business that are addressed in our filings with the Securities and Exchange Commission (“SEC”) that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Certain information included in this press release may supersede or supplement forward-looking statements in our other Exchange Act reports filed with the SEC. We do not intend to update any forward-looking statement to conform such statements to actual results or to changes in our expectations, except as required by applicable law or regulation.


EMCORE CORPORATION



Condensed Consolidated Statement of Operations



(in thousands, except for per share data)



(unaudited)

               
    For the three months ended  
    December 31,  
       2020        2019    
Revenue   $ 33,426     $ 25,482       
Cost of revenue     20,854       18,008    
Gross profit     12,572       7,474    
Operating expense:               
Selling, general, and administrative     5,798       5,887    
Research and development     4,296       4,642    
Gain on sale of assets     (29 )     (1,602 )  
Total operating expense     10,065       8,927    
Operating income (loss)     2,507       (1,453 )  
Other income:               
Interest expense, net     (49 )     (15 )  
Foreign exchange gain     237       147    
Total other income     188       132    
Income (loss) before income tax expense     2,695       (1,321 )  
Income tax expense     (126 )     (14 )  
Net income (loss)   $ 2,569     $ (1,335 )  
Foreign exchange translation adjustment     (10 )     (36 )  
Comprehensive income (loss)   $ 2,559     $ (1,371 )  
Per share data:               
Net income (loss) per basic share   $ 0.09     $ (0.05 )  
Weighted-average number of basic shares outstanding     29,503       28,832    
Net income (loss) per diluted share   $ 0.08     $ (0.05 )  
Weighted-average number of diluted shares outstanding     30,377       28,832    


EMCORE CORPORATION



Condensed Consolidated Balance Sheets



(in thousands)



(unaudited)

             
    December 31,   September 30,
    2020     2020  
ASSETS              
Current assets:              
Cash and cash equivalents   $ 31,120     $ 30,390  
Restricted cash     38       148  
Accounts receivable, net of allowance of $234 and $227, respectively     27,276       25,324  
Contract assets     582       1,566  
Inventory     27,855       25,525  
Prepaid expenses and other current assets     4,283       5,589  
Assets held for sale     1,661       1,568  
Total current assets     92,815       90,110  
Property, plant, and equipment, net     20,558       21,052  
Goodwill     69       69  
ROU assets     14,262       14,566  
Other intangible assets, net     193       202  
Other non-current assets     229       242  
Total assets   $ 128,126     $ 126,241  
LIABILITIES and SHAREHOLDERS’ EQUITY              
Current liabilities:              
PPP liability – current   $ 1,093     $  
Accounts payable     17,158       16,484  
Accrued expenses and other current liabilities     9,650       11,577  
ROU liability – current     979       992  
Total current liabilities     28,880       29,053  
PPP liability – non-current     5,395       6,488  
ROU liability – non-current     13,481       13,735  
Asset retirement obligations     2,041       2,022  
Other long-term liabilities     794       794  
Total liabilities     50,591       52,092  
Commitments and contingencies              
Shareholders’ equity:              
Common stock, no par value, 50,000 shares authorized; 36,693 shares issued and 29,783 shares
outstanding as of December 31, 2020; 36,461 shares issued and 29,551 shares outstanding as of September 30, 2020
    745,188       744,361  
Treasury stock at cost; 6,910 shares     (47,721 )     (47,721 )
Accumulated other comprehensive income     908       918  
Accumulated deficit     (620,840 )     (623,409 )
Total shareholders’ equity     77,535       74,149  
Total liabilities and shareholders’ equity   $ 128,126     $ 126,241  


EMCORE CORPORATION


Reconciliations of GAAP to Non-GAAP Financial Measures

             
    Three Months Ended
    Dec 31, 2020   Sep 30, 2020
       1Q21      4Q20
Gross Profit   $ 12,572     $ 12,463  
Gross Margin     38 %     37 %
             

Adjustments:
            
Stock-based compensation     141       194  
Asset retirement obligation (ARO) accretion     19       8  
Amortization of acquired intangibles     9       9  
Total adjustments     169       211  
             
Non-GAAP Gross Profit   $ 12,741     $ 12,674  
Non-GAAP Gross Margin     38 %     38 %

             
    Three Months Ended
    Dec 31, 2020   Sep 30, 2020
       1Q21      4Q20
Operating Expenses   $ 10,065     $ 11,850  
Stock-based compensation     (762 )     (697 )
Severance and restructuring charges     (41 )     (5 )
CATV transition – gain on sale of asset     29       55  
Litigation-related expenses           (1,464 )
Gain/loss due to change in ARO estimate            
Gain/loss on sale of assets            
Non-GAAP Operating Expenses   $ 9,291     $ 9,739  

             
    Three Months Ended
    Dec 31, 2020   Sep 30, 2020
       1Q21      4Q20
Operating Profit   $ 2,507     $ 613  
Operating Margin     8 %     2 %
             

Adjustments:
            
Stock-based compensation     903       891  
Asset retirement obligation (ARO) accretion     19       8  
Amortization of acquired intangibles     9       9  
Severance and restructuring charges     41       5  
CATV transition – gain on sale of asset     (29 )     (55 )
Litigation-related expenses           1,464  
Total adjustments     943       2,322  
             
Non-GAAP Operating Profit     3,450       2,935  
Non-GAAP Operating Margin     10 %     9 %
             
Depreciation     996       1,108  
Adjusted EBITDA   $ 4,446     $ 4,043  
Adjusted EBITDA %     13 %     12 %

             
    Three Months Ended
    Dec 31, 2020   Sep 30, 2020
       1Q21      4Q20
Net Income   $ 2,569     $ 703  
Earnings Per Share Basic     0.09       0.02  
Earnings Per Share Diluted     0.08       0.02  
             

Adjustments:
            
Stock-based compensation     903       891  
Asset retirement obligation (ARO) accretion     19       8  
Amortization of acquired intangibles     9       9  
Severance and restructuring charges     41       5  
CATV transition – gain on sale of asset     (29 )     (55 )
Litigation-related expenses           1,464  
Foreign currency gain     (237 )     (227 )
Income tax expense     126       87  
Total adjustments     832       2,182  
             
Non-GAAP Net Income     3,401       2,885  
Non-GAAP Earnings Per Share Basic     0.12       0.10  
Non-GAAP Earnings Per Share Diluted     0.11       0.10  
             
Interest expense, net     49       50  
Depreciation     996       1,108  
Adjusted EBITDA   $ 4,446     $ 4,043  
Adjusted EBITDA %     13 %     12 %

                             
    Three Months Ended       Three Months Ended
       Dec 31, 2020   Sep 30, 2020             Dec 31, 2020   Sep 30, 2020
    1Q21   4Q20       1Q21   4Q20

Aerospace and Defense
             
Broadband
                 
Gross Profit   $ 4,100     $ 4,501     Gross Profit   $ 8,472     $ 7,962  
Gross Margin     30 %     31 %   Gross Margin     43 %     42 %
                             
Adjustments:               Adjustments:            
Stock-based compensation     91       154     Stock-based compensation     50       40  
Asset retirement obligation (ARO) accretion               Asset retirement obligation (ARO) accretion     19       8  
Amortization of acquired intangibles     9       9     Amortization of acquired intangibles            
Total adjustments     100       163     Total adjustments     69       48  
                             
Non-GAAP Gross Profit   $ 4,200     $ 4,664     Non-GAAP Gross Profit   $ 8,541     $ 8,010  
Non-GAAP Gross Margin     31 %     32 %   Non-GAAP Gross Margin     43 %     42 %
                             
                             

Aerospace and Defense
             
Broadband
           
R&D Expenses   $ 3,686     $ 5,574     R&D Expenses   $ 610     $ 662  
Stock-based compensation     (123 )     (70 )   Stock-based compensation     (80 )     (42 )
Litigation-related expenses           (1,464 )   Litigation-related expenses            
Non-GAAP R&D Expenses   $ 3,563     $ 4,040     Non-GAAP R&D Expenses   $ 530     $ 620  

Contact:

EMCORE Corporation
Tom Minichiello
(626) 293-3400
[email protected]



Avante Logixx Inc. to Release Results for the Quarter Ended December 31, 2020 After Market Close on Thursday, February 25, 2021


Not for distribution to U.S. news wire services or for dissemination in the United States

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Avante Logixx Inc. (TSX.V: XX) (OTC: ALXXF) (“Avante” or the “Company”) is pleased to announce that it will release its financial results for the third quarter ended December 31, 2020 after market close on Thursday, February 25, 2021 and a news release will be disseminated at that time with an earnings call at 8:30 AM EST on Friday, February 26, 2021.


CONFERENCE CALL

Avante will be hosting a conference call to discuss the above financial results on Friday, February 26, 2021, at 8:30 AM EST.

Dial in details are as follows:
Local: (+1) 416-764-8658   Toll Free: (+1) 888-886-7786   Conference ID: 36447111
         
Playback details below, available until March 26, 2021:
Local: (+1) 416-764-8692   Toll Free: (+1) 877-674-7070   Playback Pin: 447111#


This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities described herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. The securities described herein have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.

About Avante Logixx Inc.

Avante Logixx Inc. (TSXV: XX) is a Toronto based provider of high end security services. We acquire, manage and build industry leading businesses which provide specialized, mission-critical solutions that address the needs of our customers. Our businesses continuously develop innovative solutions that enable our customers to achieve their objectives. With an experienced team and a proven track record of solid growth, we are taking steps to establish a broad portfolio of security businesses to provide our customers and shareholders with exceptional returns. Please visit our website at www.avantelogixx.com and consider joining our investor email list.

Avante Logixx Inc.

Craig Campbell
CEO
(416) 923-6984
[email protected]



AVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (February 18, 2021 at 8:30 am Melbourne time).

Authorized for release by the Chief Executive Officer of AVITA Medical, Inc.

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

 
FOR FURTHER INFORMATION:

U.S. Media

Sam Brown, Inc.
Christy Curran
Phone +1-615-414-8668
[email protected]

O.U.S. Media
Rudi Michelson
Phone +61 (0)3 9620 3333
Mobile +61 (0)411 402 737
[email protected]

Investors

Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
[email protected]



Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups

Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits

PR Newswire

THOUSAND OAKS, Calif., Feb. 3, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.

As part of the sponsorship, Amgen will launch one “Amgen Golden Ticket” award each year for three years, providing winners with one year of lab space at BioLabs as well as additional facility benefits and connections to Amgen’s scientific and business leaders.

“Recognizing the growing biotech ecosystem in Southern California, Amgen’s sponsorship of the Golden Ticket with BioLabs aims to further foster early-stage life science companies right in the backyard of Amgen’s headquarters,” said Philip Tagari, Ph.D., vice president of Therapeutic Discovery at Amgen. “It’s very rewarding to be part of the growing energy, reach, and enthusiasm of the many talented scientific entrepreneurs across the broader Los Angeles area. BioLabs is a model for how life science startups can grow and thrive in a rapidly emerging bioscience community.”

“Having Amgen join BioLabs at TLI as a significant sponsor sends a clear message about how Los Angeles has progressed as a major bioscience hub and how far our shared laboratory facility has come in just over a year of operation,” said Keith B. Hoffman, Ph.D., senior vice president of Business Development and Technology Transfer at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. “I’m extremely proud that we were able to bring the BioLabs organization to Los Angeles and that the BioLabs facility at TLI now houses the highest concentration of promising bioscience startups in the greater Los Angeles region. This partnership with Amgen represents another significant step in the rapid expansion and reach of the Los Angeles bioscience community within and surrounding counties in Southern California. I’m honored to add Amgen’s substantial reputation and reach to our member companies already in the space, and those who will join us in the future.”

“We’re thrilled that Amgen has joined as our newest sponsor and look forward to working with the Amgen team to support these early-stage entrepreneurs and to help accelerate development of new therapies to improve human health,” said BioLabs President & CEO Johannes Fruehauf, M.D., Ph.D. “With their deep expertise as developers of biotech-based drugs, Amgen is an ideal partner for many of BioLabs’ resident companies working on promising new biopharmaceuticals.”

Amgen supports life science start-ups through Golden Ticket awards and affiliated engagement in other Biotech Innovative hubs, including San Francisco, Boston and Toronto.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

About The Lundquist Institute: Research with reach™
The Lundquist Institute is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (Ph.D.s, M.D.s, and M.D./Ph.D.s) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases. Find out more at https://lundquist.org.

About BioLabs LA at The Lundquist Institute
Encompassing the entire third floor of The Lundquist Institute’s new Medical Research Lab building, BioLabs LA offers shared lab facilities designed for high-potential, early-stage life since companies. BioLabs creates co-working communities that pair premium, fully equipped and supported lab and office space with unparalleled access for entrepreneurs to networking, industry partners, and capital. Find out more at https://www.biolabs.io/la.

CONTACT:

Amgen
Jessica Akopyan, (805) 447-0974, [email protected] (media)

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Keith B. Hoffman, Ph.D., (310) 974-9301, [email protected] 

BioLabs LA
Gary Olsem, (310) 618-6892, [email protected] 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-sponsors-golden-ticket-at-biolabs-la-at-the-lundquist-institute-to-help-accelerate-life-science-startups-301221617.html

SOURCE Amgen

Align Technology Announces Commercial Availability of Invisalign® G8 With New SmartForce® Aligner Activation Features Globally

Latest evolution in SmartForce innovation improves treatment predictability for frequently treated case types

SAN JOSE, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) today announced the commercial availability of Invisalign G8 with SmartForce® Aligner Activation, the company’s latest biomechanics innovations. Invisalign G8 is informed by the company’s foundational biomechanics for clear aligners and its database of more than 9 million Invisalign patients to optimize tooth movements and further improve predictability for frequently treated crowding, crossbite, and deep bite cases. The company previously announced that Invisalign G8 would be available in the first quarter of 2021.

With SmartForce® Aligner Activation, select areas of the aligner surface are specifically contoured to apply optimal forces to the tooth surfaces to control the location, direction and intensity of the force to produce the desired outcome and minimize unwanted movement. Specific, strategic contact areas between the aligner and the tooth are created by SmartForce® Aligner Activation and work in concert with SmartForce® features for even greater control of the force systems.

Invisalign G8 with new SmartForce® Aligner Activation ensures sufficient and consistent activation in every aligner stage to help doctors get more of the desired movements from every aligner in the treatment of crowding, crossbite, and deep bite.

  • For crowding and crossbite cases:
    – SmartForce® Aligner Activation aids in posterior arch expansion by working synergistically with New Optimized Expansion Support attachments or Optimized Expansion Support and Rotation attachments to reduce the potential for buccal crown tipping during posterior arch expansion.
  • For deep bite cases:
    – SmartForce® Aligner Activation supports anterior intrusion with improvements in the treatment plan set-ups to level the Curve of Spee and demonstrates up to 2x improvement in predictability of incisor intrusion.

In addition, with Invisalign G8, doctors can now select automatic placement of Precision Bite Ramps during the prescription process. Data demonstrates that Precision Bite Ramps improve lower intrusion in deep bite cases.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 9.6 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad® CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.   

Align Technology   Zeno Group
Madelyn Homick Sarah Johnson
(408) 470-1180 (828) 551-4201
[email protected] [email protected]



Align Technology Announces the iTero Element Plus Series Next Generation of Scanners and Imaging Systems

A series of new solutions feature advanced technology and capabilities designed to improve the scanning experience, increase practice productivity, and drive higher patient treatment conversion

TEMPE, Ariz. and OR YEHUDA, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) today announced the availability of the iTero Element® Plus Series, which expands the company’s portfolio of iTero Element scanners and imaging systems to include new solutions that serve a broader range of the dental market.

The new iTero Element Plus Series of scanners and imaging systems builds on the success of the award-winning iTero Element family and offers all of the existing orthodontic and restorative digital capabilities doctors have come to rely on — plus faster processing time and advanced visualization capabilities for a seamless scanning experience in a new sleek, ergonomically designed package. Available in both cart and mobile configurations, the iTero Element Plus Series offers increased flexibility and mobility. The mobile configuration makes the power of the iTero Element Plus Series portable with a medical grade, compact mobile scanner solution that delivers the same high-quality images as the cart configuration.

“We are committed to meeting doctors’ evolving needs and designed the iTero Element Plus Series to help them provide the best clinical care for their patients, increase practice growth, and easily integrate digital scanning and imaging into their clinics as a core part of their digital workflow,” said Yuval Shaked, Align Technology, senior vice president and managing director, iTero scanner and services business. “With over 20 years of innovation in digital orthodontics and dentistry, including intraoral scanners and digital workflows, we are focused on bringing the latest technology to doctors and their patients. We engineered the iTero Element Plus Series with the latest computing power, a dedicated AI chip, and new AI-based features as well as an easy upgrade path — making it right for today’s needs and ready for tomorrow.”

The iTero Element Plus Series of solutions offer restorative and orthodontic digital workflows with:

  • Enhanced visualization for optimized patient experience, with higher brightness for clearer and more vivid images, and a fully integrated 3D intraoral camera**.
  • Faster, seamless scanning: 20 percent less waiting time for scans to process***.
  • Future AI-based features.
  • The iTero Element 5D Plus imaging system includes NIRI technology, which aids in the detection of interproximal caries. The iTero Element 5D Plus Lite imaging system allows for easy NIRI activation via a software upgrade.  

Dr. Chad Duplantis, a dentist in Fort Worth, Texas who participated in the iTero Element Plus Series limited market release said, “The continued innovation that Align brings with each iTero Element scanner elevates the standard of care that I am able to provide to my patients. The iTero Element 5D Plus imaging system allows me to be more productive with increased scanning speed, as well as improve patient communication and treatment conversion with the advanced visualization capabilities.”

The iTero Element Plus Series cart configuration is commercially available in the United States, Canada, European Union countries, Norway, Switzerland, United Kingdom, Australia, New Zealand, Hong Kong, and India with availability expected in other markets throughout 2021 and 2022. The iTero Element Plus Series mobile configuration is expected to be available pending regulatory approvals on a market-by-market basis.

Information about the iTero Element Plus Series can be found at http://www.itero.com

*availability per market and region may differ. Speak with your sales rep to find out which solutions are available in your location.

**the fully integrated 3D intraoral camera is available in the iTero Element 5D Plus and iTero Element 5D Plus Lite imaging systems.

***
Data on file at Align Technology, as of, December 22, 2020.


About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 9.6 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit http://www.exocad.com.


Align Technology

Zeno Group
Madelyn Homick Sarah Johnson
408-470-1180 (828) 551 4201
[email protected] [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e4804e68-18f8-47eb-95de-eb536922a61a



Technology Integration Group Canada (TIG) expands ThinkOn partnership to provide secure cloud solutions to Government of Canada

Partnership extends Canadian Government’s ability to accelerate digital transformation of citizen services and ensures security of sensitive data in the cloud

OTTAWA, Feb. 03, 2021 (GLOBE NEWSWIRE) — Technology Integration Group (TIG), an IT solution integrator providing datacenter and private cloud solutions to Canadian Government and Commercial Organizations for over 20 years has announced an expanded partnership with ThinkOn, Canada’s only wholesale provider of cloud solutions, certified for Public B data Storage by Shared Services Canada.

TIG and ThinkOn initiated a partnership in 2016 to respond to the growing need by Canadian governments for a made in Canada cloud solution. From 2017 to 2020 they have together been providing cloud services for government agencies with applications and data rated “Protected A”, or non-sensitive data.

With TIG’s assistance, ThinkOn was selected as one of the cloud solution providers earlier last year for Protected B data, which has much more stringent data security requirements. Agencies require these enhanced security cloud solutions, resident in Canada, to accelerate the digitization of government services, especially in response to the pandemic.

“TIG is uniquely positioned to help our Federal Department and Agency partners design and architect secure hosted cloud solutions.” Said Paul Cooper, President, TIG Canada. “We’ve been solving data center, private cloud, backup, recovery, and archiving needs for over 20 years and we understand how different these needs are compared to the commercial sector. ThinkOn has been able to allow us to extend that expertise into true hybrid cloud solutions.”

“TIG has been an invaluable partner.” Said Craig McLellan, Founder and CEO, ThinkOn. “Our combined efforts have enabled us to fully comprehend the Federal government’s need for security, agility, and cost containment and were instrumental to the development of our Protected B Data Center solutions.”

About Technology Integration Group

TIG is a premier ISO 9001:2008 certified, full-service IT systems integrator, with 33 years of experience providing end-to-end technology and IT infrastructure solutions to customers with complex environments, including the Canadian Government. www.tig-canada.ca

About ThinkOn Inc.

ThinkOn is an exclusive wholesale provider of cloud infrastructure and data management services with over 150 partners and over 1,100 end subscribers in the commercial and public sector. ThinkOn’s cloud is engineered for high availability, reliability, and scalability to meet the requirements of every government workload. Headquartered in Toronto, the company delivers true data protection and privacy with a government compliant service delivery infrastructure spanning three regions in Canada.


CONTACT:

Paul Cooper, President
Technology Integration Group Canada
EMAIL: [email protected]



Easterly Government Properties Schedules Fourth Quarter 2020 Earnings Release and Conference Call

Easterly Government Properties Schedules Fourth Quarter 2020 Earnings Release and Conference Call

WASHINGTON–(BUSINESS WIRE)–
Easterly Government Properties, Inc. (NYSE: DEA) today announced that the Company will release its fourth quarter 2020 financial results on February 24, 2021.

A conference call will be held Wednesday, February 24, 2021 at 10:00am Eastern Standard time. The management team will review fourth quarter performance, discuss recent events and conduct a question-and-answer session.

Webcast:

The conference call will be available in the Investor Relations section of the Company’s website at ir.easterlyreit.com. To listen to a live broadcast, please visit the site at least 15 minutes prior to the scheduled start time in order to register and to download and install any necessary audio software. A replay of the call will also be available for ten business days on the Company’s website.

To Participate in the Conference Call:

Dial in at least 5 minutes prior to start time:

Domestic: 877-705-6003

International: 201-493-6725

Conference Call Playback:

Domestic: 844-512-2921

International: 412-317-6671

Passcode: 13715203

The playback can be accessed through March 10, 2021.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE:DEA) is based in Washington, D.C. and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

Easterly Government Properties, Inc.

Lindsay S. Winterhalter

Vice President, Investor Relations & Operations

202-596-3947

[email protected]

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Other Government Commercial Building & Real Estate Construction & Property Finance Banking REIT Public Policy/Government Professional Services White House/Federal Government

MEDIA:

Logo
Logo